Holen Sie sich die Stockscreener-App
4.12
3.00%
0.12
Vorhandelsmarkt:
4.00
-0.12
-2.91%
Schlusskurs vom Vortag:
$4.00
Offen:
$4.16
24-Stunden-Volumen:
1.17M
Relative Volume:
1.31
Marktkapitalisierung:
$321.42M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-69.31M
KGV:
-3.2441
EPS:
-1.27
Netto-Cashflow:
$-62.80M
1W Leistung:
+9.57%
1M Leistung:
+62.85%
6M Leistung:
-24.26%
1J Leistung:
+24.47%
1-Tages-Spanne:
$3.97
$4.20
1-Wochen-Bereich:
$3.58
$4.20
52-Wochen-Spanne:
$2.215
$6.1856
Rezolute Inc Stock (RZLT) Company Profile
Firmenname
Rezolute Inc
Sektor
Branche
Telefon
650-206-4507
Adresse
275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY
Vergleichen Sie RZLT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RZLT
Rezolute Inc
|
4.12 | 321.42M | 0 | -69.31M | -62.80M | -1.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Rezolute Inc Stock (RZLT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-05 | Eingeleitet | Wedbush | Outperform |
| 2024-08-27 | Eingeleitet | Guggenheim | Buy |
| 2024-07-17 | Eingeleitet | BTIG Research | Buy |
| 2024-06-04 | Eingeleitet | Craig Hallum | Buy |
| 2024-04-09 | Eingeleitet | Maxim Group | Buy |
| 2022-08-02 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-06-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-09-08 | Eingeleitet | ROTH Capital | Buy |
| 2021-05-27 | Eingeleitet | Oppenheimer | Outperform |
| 2021-05-25 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Rezolute Inc Aktie (RZLT) Neueste Nachrichten
Rezolute Gets US FDA Breakthrough Therapy Designation for Hypoglycemia Treatment - marketscreener.com
Rezolute (RZLT) Gains FDA Breakthrough Status for Hypoglycemia Treatment | RZLT Stock News - GuruFocus
FDA grants breakthrough status to Rezolute’s hypoglycemia therapy - Investing.com
FDA grants breakthrough status to Rezolute’s hypoglycemia therapy By Investing.com - Investing.com India
Rezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor Hyperinsulinism - The Manila Times
FDA Breakthrough: New Drug Shows Promise Against Life-Threatening Tumor-Induced Hypoglycemia - Stock Titan
Renaissance Technologies LLC Reduces Stake in Rezolute, Inc. (NASDAQ:RZLT) - Defense World
Rezolute Inc (RZLT) Stock: Navigating Market Highs and Lows in 52 Weeks - investchronicle.com
Rezolute to Participate in Upcoming Investor Conferences - The Manila Times
Rezolute: RZ402 Could Be A Surprise Candidate In The Making (NASDAQ:RZLT) - Seeking Alpha
Wedbush gives an Outperform recommendation for Rezolute Inc (RZLT) - knoxdaily.com
Market Recap: Rezolute Inc (RZLT)’s Positive Momentum, Closing at 3.86 - DWinneX
Rezolute’s $90 Million Common Stock Offering - Global Legal Chronicle
Rezolute (NASDAQ:RZLT) Given Buy Rating at HC Wainwright - Defense World
Geode Capital Management LLC Has $2.54 Million Stock Holdings in Rezolute, Inc. (NASDAQ:RZLT) - Defense World
Rezolute Closes $96.9 Million Underwritten Offering - TipRanks
Rezolute (RZLT) SunRIZE Trial Progresses Without Changes | RZLT Stock News - GuruFocus
Analysts Set Rezolute, Inc. (NASDAQ:RZLT) PT at $26.43 - Defense World
Rezolute, Inc. Announces Closing of Underwritten Offering | RZLT Stock News - GuruFocus
Rezolute Closes Underwritten Share Offering - marketscreener.com
Rezolute, Inc. Announces Closing of Underwritten Offering - The Manila Times
Rezolute, Inc. Closes $96.9 Million Offering of Common Stock and Pre-Funded Warrants - Nasdaq
Rezolute Secures Massive $97M Funding: Blackstone, Federated Hermes Back Oversubscribed Round - Stock Titan
Mintz Advises on $90 Million Underwritten Offering by Rezolute - Mintz
Rezolute gets positive recommendation from IDMC to continue Ersodetug study - MSN
Rezolute Inc [RZLT] Records 50-Day SMA of $3.52 - knoxdaily.com
Investor’s Delight: Rezolute Inc (RZLT) Closes Strong at 3.97, Up 27.65 - DWinneX
Rezolute’s insulin disorder trial gets nod to move forward with no need to add new patients - koreabiomed.com
Rezolute’s sunRIZE trial to proceed without changes By Investing.com - Investing.com South Africa
Rezolute targets $90 million fundraise after positive late-stage trial newsSan Francisco Business Times - The Business Journals
Rezolute sets $90 million stock and warrant offering By Investing.com - Investing.com South Africa
Rezolute Announces Pricing of Direct Stock Offering - TipRanks
Rezolute Prices $90 Mln Offering With Common Stock And Pre-Funded Warrants - Nasdaq
Rezolute 'Thrilled' With Positive Review Of Genetic Disorder Trial, Expects Topline Results In December - Benzinga
Biotech Stock Surges After Encouraging Data Monitoring Committee Recommendation - The Globe and Mail
Rezolute announces DMC recommendation to continue Phase 3 sunRIZE study - TipRanks
Rezolute Raises $90 Mln Through Stock And Warrant Offering To Support HI Drug Pipeline - Nasdaq
Rezolute stock rises after pricing $90M securities offering - MSN
Rezolute’s Promising Clinical Developments and Positive Outlook: A Buy Recommendation by Yun Zhong - TipRanks
Rezolute (RZLT) Launches $90 Million Stock Offering Priced at $3 - GuruFocus
Rezolute Receives Positive DMC Recommendation for Phase 3 Study - TipRanks
Rezolute Gets Independent DMC's Positive Recommendation to Continue Ersodetug Study -- Shares Surge Pre-Bell - marketscreener.com
Rezolute sets $90 million stock and warrant offering - Investing.com Australia
Rezolute’s sunRIZE trial to proceed without changes - Investing.com
Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants | RZLT Stock News - GuruFocus
Rezolute (RZLT) Advances Phase 3 sunRIZE Trial Following Positiv - GuruFocus
Rezolute Announces Positive Recommendation After Independent Interim Analysis of Phase 3 sunRIZE Study of Ersodetug in Congenital Hyperinsulinism ('HI”) - The Manila Times
Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants - The Manila Times
Rezolute, Inc. Announces Pricing of Underwritten Offering for 20.8 Million Shares at $3.25 Per Share - Nasdaq
Rezolute Announces Pricing Of Offering Of $90 Million Of Common Stock And Pre-Funded Warrants - marketscreener.com
Rezolute's Massive $90M Stock Offering Draws Blackstone, Federated Hermes Investment Giants - Stock Titan
Finanzdaten der Rezolute Inc-Aktie (RZLT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.39%
3.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):